Vilobelimab: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies 26% 1 368 Improvement, Studies, Patients Relative Risk Mortality 26% 1 368 RCTs 26% 1 368 Late 26% 1 368 Vilobelimab for COVID-19 c19early.org December 2025 Favorsvilobelimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] death 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Effect extraction pre-specified(most serious outcome) Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] death 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Effect extraction pre-specified(most serious outcome) Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] death 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Effect extraction pre-specified(most serious outcome) Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] death 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Late treatment 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk All studies 26% 0.74 [0.52-1.04] 177 (n) 191 (n) 26% lower risk 1 vilobelimab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.082 Effect extraction pre-specified(most serious outcome) Favors vilobelimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PANAMO Vlaar (DB RCT) 26% 0.74 [0.52-1.04] death 177 (n) 191 (n) Ventilated patients Improvement, RR [CI] Treatment Control PANAMO Vlaar (DB RCT) 27% 0.73 [0.50-1.06] death 177 (n) 191 (n) Ventilated patients Vilobelimab COVID-19 outcomes c19early.org December 2025 Favors vilobelimab Favors control